Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
7.30
+0.13 (1.81%)
At close: Sep 26, 2025, 4:00 PM EDT
7.36
+0.06 (0.82%)
After-hours: Sep 26, 2025, 4:14 PM EDT
Nutriband Revenue
Nutriband had revenue of $622.45K in the quarter ending July 31, 2025, with 40.56% growth. This brings the company's revenue in the last twelve months to $2.58M, up 42.92% year-over-year. In the fiscal year ending January 31, 2025, Nutriband had annual revenue of $2.14M with 2.60% growth.
Revenue (ttm)
$2.58M
Revenue Growth
+42.92%
P/S Ratio
31.37
Revenue / Employee
$198,312
Employees
13
Market Cap
87.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
Jan 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTRB News
- 2 days ago - Nutriband Inc. to Present at the MicroCap Rodeo Conference - GlobeNewsWire
- 17 days ago - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - GlobeNewsWire
- 23 days ago - Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000 - GlobeNewsWire
- 5 weeks ago - Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025 - GlobeNewsWire
- 6 weeks ago - Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election - GlobeNewsWire
- 7 weeks ago - FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 2 months ago - Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval - GlobeNewsWire
- 3 months ago - Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval - GlobeNewsWire